These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36946070)

  • 1. Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study.
    Tharoor H; Maran S; Chandan AK; Pari M; Rao S; Durairaj J
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01074. PubMed ID: 36946070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Khoaie-Ardakani MR; Shahmoradi Z; Alavi AR; Afarideh M; Shalbafan MR; Ghazizadeh-Hashemi M; Akhondzadeh S
    Psychiatry Res; 2018 Apr; 262():94-101. PubMed ID: 29427913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia.
    Chengappa KN; Turkin SR; DeSanti S; Bowie CR; Brar JS; Schlicht PJ; Murphy SL; Hetrick ML; Bilder R; Fleet D
    Schizophr Res; 2012 Dec; 142(1-3):145-52. PubMed ID: 23099060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Hajizadeh-Zaker R; Ghajar A; Mesgarpour B; Afarideh M; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):74-81. PubMed ID: 29027815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.
    Levkovitz Y; Mendlovich S; Riwkes S; Braw Y; Levkovitch-Verbin H; Gal G; Fennig S; Treves I; Kron S
    J Clin Psychiatry; 2010 Feb; 71(2):138-49. PubMed ID: 19895780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
    Bobo WV; Woodward ND; Sim MY; Jayathilake K; Meltzer HY
    Schizophr Res; 2011 Aug; 130(1-3):106-13. PubMed ID: 21641776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Araminia B; Shalbafan M; Mortezaei A; Shirazi E; Ghaffari S; Sahebolzamani E; Mortazavi SH; Shariati B; Ardebili ME; Aqamolaei A; Naderi S; Akhondzadeh S
    J Affect Disord; 2020 Apr; 267():131-136. PubMed ID: 32063564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
    Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
    Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Huerta-Ramos E; Iniesta R; Ochoa S; Cobo J; Miquel E; Roca M; Serrano-Blanco A; Teba F; Usall J
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):223-31. PubMed ID: 24342775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.